Fortress Biotech at the H.C. Wainwright Conference
MIAMI, Fortress Biotech, Inc. (Nasdaq: FBIO) is gearing up to make a significant impact at the H.C. Wainwright 26th Annual Global Investment Conference. This event offers a valuable platform for the company to present its innovative strategies aimed at enhancing shareholder value through product revenue, equity holdings, and a variety of revenue streams. The presentation will be led by the company’s visionary leader, Lindsay A. Rosenwald, M.D., who holds the roles of Chairman, President, and Chief Executive Officer at Fortress.
Details of the Investment Conference
Conference attendees can look forward to on-demand access to the corporate overview beginning on September 9, 2024, at 7:00 a.m. ET. In addition to the presentation, Fortress will conduct one-on-one meetings throughout the conference, further reinforcing its appeal as a promising investment opportunity.
About Fortress Biotech
Fortress Biotech, Inc. distinguishes itself in the biopharmaceutical sector by focusing on acquiring and advancing a diverse portfolio of assets designed to maximize long-term shareholder value. With seven marketed prescription pharmaceutical products and a remarkable array of over 20 programs currently in development, Fortress is making notable progress across various therapeutic areas.
Diverse Pipeline and Market Focus
The company strategically concentrates on six large-market sectors, including oncology, rare diseases, and gene therapy, creating avenues for significant shareholder returns. Its efficient operating structure accelerates drug development, enabling Fortress to leverage its extensive biopharmaceutical expertise. By forming strategic partnerships with leading institutions, Fortress enhances the potential of each product, ensuring a strong competitive advantage.
Dedication to Shareholder Value
At the core of Fortress Biotech's mission is a steadfast commitment to generating value for investors. The company's innovative business model allows it to utilize its industry expertise to identify and develop high-potential product candidates. By continually expanding its portfolio, Fortress aims to deliver substantial returns to its shareholders.
Engaging with Fortress Biotech
For those interested in discovering more about Fortress Biotech, the company offers direct contact options for inquiries. Jaclyn Jaffe is available for company information at (781) 652-4500, while media relations can be reached through Tony Plohoros at 6 Degrees at (908) 591-2839. Fortress encourages all interested parties to reach out for additional information regarding their innovative projects and investment opportunities.
Frequently Asked Questions
What is Fortress Biotech's core business focus?
Fortress Biotech specializes in acquiring and advancing biopharmaceutical assets to enhance long-term value for its shareholders.
Who will be presenting at the conference?
Lindsay A. Rosenwald, M.D., who serves as the Chairman, President, and CEO, will present an overview at the conference.
When can attendees view the presentation?
The presentation will be available on-demand starting September 9, 2024, at 7:00 a.m. ET.
How many pharmaceutical products does Fortress have?
Fortress Biotech currently has seven marketed prescription pharmaceutical products.
What areas does Fortress Biotech's pipeline target?
The pipeline focuses on oncology, rare diseases, and gene therapy, among other large-market sectors.
